Should status II patients be removed from the pediatric heart transplant waiting list? A multi-institutional study

J. K. Kirklin, D. C. Naftel, R. L. Caldwell, F. B. Pearce, H. Bartlett, Paolo Rusconi, C. White-Williams, B. V. Robinson

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The survival benefit of cardiac transplantation (CTx) among Status 2 (stable outpatient) adult recipients has been questioned, but few studies have addressed this issue in pediatric patients. This study examined the following hypothesis: "Status 2 pediatric recipients have a survival benefit with CTx." Methods: Between 1993 and 2003, 2,375 patients were listed for CTx at 24 institutions; 614 (26%) of these patients were Status 2. By multivariate competing outcomes hazard function analysis, death after listing and post-transplant survival were analyzed. Results: A single-phase hazard function described the risk of death after listing, with 20% actual mortality within 2 months after Status 1 listing. The "natural history" of Status 2-listed patients was estimated by the risk of death, whereas waiting and risk of deterioration to Status 1 at CTx (weighted by the probability of death at 3 months after Status 1 listing). At 4 months after CTx, survival with CTx exceeded the predicted "natural Hx" survival in all diagnostic categories out to 4 years of follow-up. Conclusions: Pediatric patients currently listed as Status 2 have a survival benefit with transplant out to at least 4 years. A pediatric allocation system restricted to Status 1 patients could only be justified if the vast majority of such patients could be transplanted within 1 to 2 months.

Original languageEnglish
Pages (from-to)271-275
Number of pages5
JournalJournal of Heart and Lung Transplantation
Volume25
Issue number3
DOIs
StatePublished - Mar 1 2006

Fingerprint

Waiting Lists
Pediatrics
Transplants
Survival
Heart Transplantation
Natural History
Outpatients
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Should status II patients be removed from the pediatric heart transplant waiting list? A multi-institutional study. / Kirklin, J. K.; Naftel, D. C.; Caldwell, R. L.; Pearce, F. B.; Bartlett, H.; Rusconi, Paolo; White-Williams, C.; Robinson, B. V.

In: Journal of Heart and Lung Transplantation, Vol. 25, No. 3, 01.03.2006, p. 271-275.

Research output: Contribution to journalArticle

Kirklin, J. K. ; Naftel, D. C. ; Caldwell, R. L. ; Pearce, F. B. ; Bartlett, H. ; Rusconi, Paolo ; White-Williams, C. ; Robinson, B. V. / Should status II patients be removed from the pediatric heart transplant waiting list? A multi-institutional study. In: Journal of Heart and Lung Transplantation. 2006 ; Vol. 25, No. 3. pp. 271-275.
@article{82e2b62a0dd04b07951c438b7b4ea6b4,
title = "Should status II patients be removed from the pediatric heart transplant waiting list? A multi-institutional study",
abstract = "Background: The survival benefit of cardiac transplantation (CTx) among Status 2 (stable outpatient) adult recipients has been questioned, but few studies have addressed this issue in pediatric patients. This study examined the following hypothesis: {"}Status 2 pediatric recipients have a survival benefit with CTx.{"} Methods: Between 1993 and 2003, 2,375 patients were listed for CTx at 24 institutions; 614 (26{\%}) of these patients were Status 2. By multivariate competing outcomes hazard function analysis, death after listing and post-transplant survival were analyzed. Results: A single-phase hazard function described the risk of death after listing, with 20{\%} actual mortality within 2 months after Status 1 listing. The {"}natural history{"} of Status 2-listed patients was estimated by the risk of death, whereas waiting and risk of deterioration to Status 1 at CTx (weighted by the probability of death at 3 months after Status 1 listing). At 4 months after CTx, survival with CTx exceeded the predicted {"}natural Hx{"} survival in all diagnostic categories out to 4 years of follow-up. Conclusions: Pediatric patients currently listed as Status 2 have a survival benefit with transplant out to at least 4 years. A pediatric allocation system restricted to Status 1 patients could only be justified if the vast majority of such patients could be transplanted within 1 to 2 months.",
author = "Kirklin, {J. K.} and Naftel, {D. C.} and Caldwell, {R. L.} and Pearce, {F. B.} and H. Bartlett and Paolo Rusconi and C. White-Williams and Robinson, {B. V.}",
year = "2006",
month = "3",
day = "1",
doi = "10.1016/j.healun.2005.10.003",
language = "English",
volume = "25",
pages = "271--275",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Should status II patients be removed from the pediatric heart transplant waiting list? A multi-institutional study

AU - Kirklin, J. K.

AU - Naftel, D. C.

AU - Caldwell, R. L.

AU - Pearce, F. B.

AU - Bartlett, H.

AU - Rusconi, Paolo

AU - White-Williams, C.

AU - Robinson, B. V.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Background: The survival benefit of cardiac transplantation (CTx) among Status 2 (stable outpatient) adult recipients has been questioned, but few studies have addressed this issue in pediatric patients. This study examined the following hypothesis: "Status 2 pediatric recipients have a survival benefit with CTx." Methods: Between 1993 and 2003, 2,375 patients were listed for CTx at 24 institutions; 614 (26%) of these patients were Status 2. By multivariate competing outcomes hazard function analysis, death after listing and post-transplant survival were analyzed. Results: A single-phase hazard function described the risk of death after listing, with 20% actual mortality within 2 months after Status 1 listing. The "natural history" of Status 2-listed patients was estimated by the risk of death, whereas waiting and risk of deterioration to Status 1 at CTx (weighted by the probability of death at 3 months after Status 1 listing). At 4 months after CTx, survival with CTx exceeded the predicted "natural Hx" survival in all diagnostic categories out to 4 years of follow-up. Conclusions: Pediatric patients currently listed as Status 2 have a survival benefit with transplant out to at least 4 years. A pediatric allocation system restricted to Status 1 patients could only be justified if the vast majority of such patients could be transplanted within 1 to 2 months.

AB - Background: The survival benefit of cardiac transplantation (CTx) among Status 2 (stable outpatient) adult recipients has been questioned, but few studies have addressed this issue in pediatric patients. This study examined the following hypothesis: "Status 2 pediatric recipients have a survival benefit with CTx." Methods: Between 1993 and 2003, 2,375 patients were listed for CTx at 24 institutions; 614 (26%) of these patients were Status 2. By multivariate competing outcomes hazard function analysis, death after listing and post-transplant survival were analyzed. Results: A single-phase hazard function described the risk of death after listing, with 20% actual mortality within 2 months after Status 1 listing. The "natural history" of Status 2-listed patients was estimated by the risk of death, whereas waiting and risk of deterioration to Status 1 at CTx (weighted by the probability of death at 3 months after Status 1 listing). At 4 months after CTx, survival with CTx exceeded the predicted "natural Hx" survival in all diagnostic categories out to 4 years of follow-up. Conclusions: Pediatric patients currently listed as Status 2 have a survival benefit with transplant out to at least 4 years. A pediatric allocation system restricted to Status 1 patients could only be justified if the vast majority of such patients could be transplanted within 1 to 2 months.

UR - http://www.scopus.com/inward/record.url?scp=33344455445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33344455445&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2005.10.003

DO - 10.1016/j.healun.2005.10.003

M3 - Article

C2 - 16507418

AN - SCOPUS:33344455445

VL - 25

SP - 271

EP - 275

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 3

ER -